HC Wainwright Reiterates Neutral Rating for Zura Bio (NASDAQ:ZURA)

HC Wainwright reissued their neutral rating on shares of Zura Bio (NASDAQ:ZURA) in a research report released on Monday,Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock. HC Wainwright also issued estimates for Zura Bio’s Q3 2025 earnings at ($0.23) EPS.

Other equities research analysts have also issued reports about the stock. Piper Sandler restated an “overweight” rating and set a $26.00 target price on shares of Zura Bio in a research report on Thursday, September 19th. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a report on Friday, October 18th. Leerink Partners assumed coverage on Zura Bio in a report on Monday, November 4th. They set an “outperform” rating and a $15.00 price objective for the company. Finally, Chardan Capital decreased their target price on Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $15.80.

Zura Bio Stock Performance

Shares of Zura Bio stock opened at $3.60 on Monday. Zura Bio has a one year low of $2.00 and a one year high of $6.35. The firm has a fifty day moving average of $4.21 and a two-hundred day moving average of $4.12.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). On average, equities research analysts forecast that Zura Bio will post -0.61 earnings per share for the current fiscal year.

Insider Transactions at Zura Bio

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the transaction, the director now directly owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. This represents a 2.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 22.10% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

A number of hedge funds and other institutional investors have recently modified their holdings of ZURA. Point72 Asset Management L.P. purchased a new stake in Zura Bio in the 2nd quarter worth approximately $8,446,000. Armistice Capital LLC boosted its holdings in shares of Zura Bio by 53.2% during the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after purchasing an additional 876,000 shares during the last quarter. Great Point Partners LLC grew its position in shares of Zura Bio by 68.3% in the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after purchasing an additional 1,884,501 shares during the period. Forefront Analytics LLC increased its stake in Zura Bio by 22.1% in the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after purchasing an additional 7,531 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new position in Zura Bio during the second quarter worth about $43,000. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.